Plain-English translation of NCT07594340 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial compares two different ways of delivering chemotherapy directly to liver tumors, both paired with two immune-boosting medications called sintilimab and bevacizumab. You'll be randomly assigned to receive either a newer infusion method (FOLFOX-HAIC) or the standard procedure (TACE), along with the same immune medications. The goal is to see which combination helps patients with advanced liver cancer live longer without their disease getting worse.
The standard treatment for intermediate-stage liver cancer doesn't work as well when tumors are large or numerous. This trial investigates whether the newer chemotherapy delivery method, combined with immune therapy, can provide better control of the cancer and improve survival outcomes for patients with more extensive disease.
You likely qualify if…
You likely don't qualify if…
You will visit the hospital or clinic every three weeks for up to one year. Depending on which group you're randomly assigned to, you'll receive either a newer infusion-based chemotherapy or the standard tumor-targeting procedure in your first four months, while also receiving immune-boosting medications throughout the year. The research team will monitor you closely with regular blood tests, imaging scans, and check-ins to track how you're responding and watch for any side effects.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
China